Led · Seed · Apr 2026

dehaze builds a purpose-built foundational AI model that processes heterogeneous healthcare datasets at scale to provide causal insights for clinicians and insurers. Its platform is designed to help healthcare payers identify individuals at risk of chronic conditions earlier, with the aim of improving intervention outcomes and reducing medical loss ratios. The company emphasizes that it is built as a foundational model for chronic disease detection rather than a chatbot or dashboard solution. dehaze says its system improves traceability and will add next-best-action recommendations to support decision-making. The company reports global customer interest and payer signings as it scales internationally.

Participated · Series A · Feb 2026

Biorce develops Aika, an AI-native platform trained on roughly one million historical clinical trials to predict risks, reduce errors, and minimize costly protocol amendments. By shortening preparation timelines and limiting amendments that can each add €500,000–€1 million and six weeks of delay, the company aims to make clinical research faster, more reliable, and more accessible. Aika is already used in oncology, neurology, and rare-disease studies and is intentionally therapy-agnostic so it can scale across diverse programmes. Backed by more than $60 million in total funding, Biorce plans to grow its workforce and open a development and R&D hub in Austin, Texas to support U.S. customers. The roadmap through early 2026 includes expanding Aika’s protocol-intelligence engine and rolling out new modules for contract management, negotiation, budget planning, and operational execution. These enhancements are designed to further improve trial efficiency and accelerate patient access to new therapies.

Participated · Seed · Nov 2025

Scripta Therapeutics combines experimental biology with artificial intelligence and advanced imaging to create and modulate disease maps based on transcriptional networks. By analysing patient-derived cellular models, the platform identifies nodes that can be targeted to shift diseased cells back to healthy phenotypes. Although broadly applicable, the company’s initial therapeutic focus is on Alzheimer’s disease and other neurodegenerative disorders, developed in collaboration with co-founder Professor Noel Buckley of the University of Oxford. The approach integrates wet-lab experimentation and computational analysis, positioning Scripta at the intersection of drug discovery and precision medicine. The recent seed financing provides $12 million of runway to expand operations and accelerate development programmes. No commercial products or revenue figures have been disclosed to date. The company’s leadership is headed by founder and CEO Peter Hamley, and its board now includes Ray Barlow as a non-executive director.

Participated · Seed · Nov 2025

Founded in 2023, Holi operates a mobile-first digital clinic that unites doctors, psychodietitians, psychologists and physiotherapists to treat obesity at its root causes. Its platform continuously analyzes patient data to fine-tune therapy, integrates GLP-1 drug tracking, and triggers human intervention only when needed, which lowers medication costs by up to 50%. Patients reportedly achieve an average 17 % body-weight reduction after 12 months—about 1.5× better than drug therapy alone. The service is sold on a subscription model and gives users access to medications such as Ozempic and Wegovy alongside behavioral coaching. With fresh capital, Holi plans to enhance diagnostics integration, automate care processes, and add engagement features to sustain motivation. The company also intends to expand beyond Poland into Southern and Eastern European markets where telemedicine adoption is rising. Prior to the current round it raised a €680 k pre-Seed in 2023, demonstrating steady investor confidence in its hybrid care model.

Led · Series A · Oct 2025

roclub offers a cloud- and AI-based teleoperation system that plugs into any monitored medtech device via a smartphone-sized connector, giving technologists secure, real-time remote control of scanners from any manufacturer. The platform supports full video and audio links between on-site staff, remote operators and patients, enabling hospitals and imaging centres to stretch scarce technologist resources, cut downtime and raise scanner utilisation. AI-assisted workflows aim to shorten patient wait times and improve diagnostic quality while allowing technologists flexible, hybrid-work setups. Founded in 2022 by Dr Matthias Issing and André Glardon after operating a large European diagnostics network, the company now serves major hospitals and outpatient providers in 11 countries. Management plans to establish roclub as the global benchmark for medtech teleoperation and to build a marketplace that matches healthcare organisations with qualified remote technologists. The new capital will support entry into the US market, continued AI-driven platform development and a headcount doubling by 2026. Prior to the current round, the company had raised a seed investment from Speedinvest and angels; no revenue figures were disclosed.